src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8050569412065003" crossorigin="anonymous">[/script]

Eli Lilly (LLY) earnings Q4 2024 newsthirst.

Eli Lilly on Thursday reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company’s quarterly earnings topped Wall Street estimates, but sales fell just short as Mounjaro saw lower realized prices. Zepbound and Mounjaro have now underperformed expectations for two straight…

Read More